{"title": "RecruitMe", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2023-01-01", "cleaned_text": "A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM subjects (Brain Tumors) |Sponsor: ||VBI Vaccines, Inc. | | The purpose of this study is to test the safety of a new vaccine, VBI-1901, and to know more about its ability to boost the response of the immune system against Cytomegalovirus. The reason for testing this vaccine in people with a brain tumor is that it might one day be used to boost the ability of the immune system to fight a certain type of brain tumor. This type of treatment for brain tumors is called immunotherapy. Investigator Andrew Lassman, MD |Are you between the ages of 18-70? || |[Yes] | |[No] |Have you been of brain cancer)? || |[Yes] | |[No] |Has your tumor come back after an initial treatment? || |[Yes] | "}